What is the recommended protocol for initiating Sublocade (buprenorphine) therapy in a patient with opioid use disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Sublocade Initiation Protocol

Patients must receive at least one dose of transmucosal buprenorphine (e.g., 4 mg sublingual) before the first Sublocade injection, and must be monitored in the healthcare setting after injection until symptoms are stable or improving. 1

Pre-Injection Requirements

Transmucosal Buprenorphine Stabilization

  • Patients not currently on buprenorphine must receive an initial dose of transmucosal buprenorphine (e.g., 4 mg) before administering the first Sublocade injection. 1
  • Patients already being treated with transmucosal buprenorphine can transition directly to Sublocade. 1
  • The FDA labeling explicitly requires verification that patients have tolerated transmucosal buprenorphine before injecting Sublocade to avoid precipitating withdrawal in patients dependent on full agonist opioids. 1

Withdrawal Assessment Before Transmucosal Buprenorphine

For patients initiating buprenorphine therapy (not already on it):

  • Wait minimum 12–24 hours after last opioid use, though longer intervals may be needed with fentanyl exposure due to tissue accumulation. 2
  • Document objective withdrawal signs using a validated scale (Clinical Opioid Withdrawal Scale [COWS] ≥8 indicating moderate withdrawal). 2
  • Administering buprenorphine too early precipitates severe withdrawal because buprenorphine's high μ-receptor affinity displaces full agonists while providing only partial agonist activity. 2

Sublocade Dosing Schedule

Initial Dosing

  • First injection: 300 mg subcutaneously 1
  • Second injection: 300 mg subcutaneously, administered as early as one week after the first injection 1
  • The ability to give the second dose after just one week (rather than waiting a full month) is critical for rapid stabilization. 1

Maintenance Dosing

  • Standard maintenance: 100 mg monthly (administered at least 26 days apart) 1
  • Consider increasing to 300 mg monthly maintenance if benefits outweigh risks for individual patients. 1
  • Patients who miss a maintenance dose should receive the next dose as soon as possible. 1

Administration Technique

Injection Site and Method

  • Subcutaneous injection ONLY—never intravenous, intramuscular, or intradermal. 1
  • Approved sites: abdomen, thigh, buttock, or back of upper arm. 1
  • Rotate injection sites between doses. 1
  • Use only the syringe and safety needle included with the product (19-gauge, 5/8-inch needle). 1

Critical Safety Warning

  • Intravenous administration causes serious harm or death—Sublocade forms a solid mass on contact with body fluids, causing occlusion, tissue damage, and potentially fatal pulmonary emboli. 1
  • Inadvertent intramuscular or intradermal administration increases risk of serious injection site reactions. 1

Post-Injection Monitoring

Immediate Monitoring Requirements

  • Monitor patients in the healthcare setting after injection to assess for worsening withdrawal or sedation. 1
  • Patients' symptoms must be stable or improving before release from the healthcare setting. 1
  • This monitoring period is mandatory per FDA labeling and addresses the risk that some patients may experience withdrawal if inadequately stabilized on transmucosal buprenorphine beforehand. 1

Ongoing Monitoring

  • Examine injection sites at subsequent visits for signs of infection or evidence of tampering/attempts to remove the depot. 1
  • Monitor liver function tests before and during treatment. 1

Opioid Overdose Reversal Agent

Naloxone Co-Prescription

  • Strongly consider recommending or prescribing naloxone (or nalmefene) when initiating or renewing Sublocade because patients with opioid use disorder have relapse potential, putting them at overdose risk. 1
  • Discuss options for obtaining naloxone: prescription, over-the-counter, or community-based programs. 1
  • Also consider prescribing for household members or close contacts at risk for accidental exposure. 1

REMS Program Requirements

  • Sublocade is only available through the restricted SUBLOCADE REMS Program due to intravenous administration risks. 1
  • Healthcare settings and pharmacies must be certified in this program and comply with REMS requirements. 1
  • This is a healthcare provider preparation and administration-only medication—patients cannot self-administer. 1

Special Considerations

Acute Pain Management

  • If opioid analgesia is required during Sublocade treatment, higher doses of full agonist opioids may be needed due to buprenorphine's high μ-receptor affinity and competitive binding. 1
  • Avoid mixed agonist-antagonist opioids (pentazocine, nalbuphine, butorphanol) as they will precipitate acute withdrawal. 3
  • Treat pain with non-opioid analgesics whenever possible. 1

Discontinuation

  • If Sublocade is discontinued, monitor patients for several months for withdrawal symptoms due to the extended-release formulation's prolonged duration. 1
  • Buprenorphine levels remain detectable for extended periods after the last injection. 4

Comprehensive Treatment Plan

  • Sublocade must be used as part of a complete treatment program including counseling and psychosocial support. 1

References

2
Guideline

Buprenorphine Induction After Recent Fentanyl Use

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

How is Sublocade (buprenorphine) administered, what are its contraindications and monitoring requirements, and what alternatives exist for treating opioid use disorder in adults?
What is the recommended buprenorphine titration schedule for induction and maintenance in opioid use disorder?
How should buprenorphine‑naloxone (Suboxone) be initiated and managed in primary care for an adult patient with opioid use disorder who is not acutely intoxicated, does not have severe respiratory depression, and does not have uncontrolled severe pain?
What are the indications for switching a patient from sublingual Suboxone (buprenorphine‑naloxone) to monthly injectable Sublocade (extended‑release buprenorphine)?
What is the indication for Sublocade (extended‑release buprenorphine) and what are its dosing schedule, including initial and maintenance doses, as well as the recommended non‑pharmacologic treatment plan to accompany it?
What is the appropriate treatment plan for a patient with gross hematuria, a history of kidney stones, bladder pain, and high ketonuria?
When should oral budesonide be stopped before a planned surgery?
Can rectal pain be caused by a sexually transmitted infection or bacterial vaginosis?
How long does intramuscular Toradol (ketorolac) last?
What is the nursing management for a patient with a left ventricular assist device (LVAD) in the intensive care unit, including hemodynamic monitoring, anticoagulation, fluid balance, right‑ventricular support, driveline care, bleeding surveillance, power source maintenance, emergency alarm response, early mobility, patient education, and pump‑thrombosis management?
Can a 40 mg valsartan tablet be split (halved)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.